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Abstract
Background—Atazanavir-associated hyperbilirubinemia can cause premature discontinuation of
atazanavir and avoidance of its initial prescribing. We used genome-wide genotyping and clinical
data to characterize determinants of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS
Clinical Trials Group protocol A5202.
Methods—Plasma atazanavir pharmacokinetics and indirect bilirubin concentrations were
characterized in HIV-1-infected subjects randomized to atazanavir/ritonavir-containing regimens.
A subset had genome-wide genotype data available.
Results—Genome-wide assay data were available from 542 subjects, of who 475 also had
estimated atazanavir clearance and relevant covariate data available. Peak bilirubin concentration
and relevant covariates were available for 443 participants. By multivariate analysis, higher peak
on-treatment bilirubin was associated with UGT1A1 rs887829 T allele (P=6.4×10−12), higher
baseline hemoglobin (P=4.9×10−13), higher baseline bilirubin (P=6.7×10−12), and slower plasma
atazanavir clearance (P=8.6×10−11). For peak bilirubin >3.0 mg/dL, the positive predictive value
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of baseline bilirubin ≥0.5 mg/dL with hemoglobin ≥14g/dL was 0.51, which increased to 0.85 with
rs887829 TT homozygosity. For peak bilirubin ≤3.0 mg/dL, the positive predictive value of
baseline bilirubin <0.5 mg/dL with hemoglobin <14 g/dL was 0.91, which increased to 0.96 with
rs887829 CC homozygosity. No polymorphism predicted atazanavir pharmacokinetics at genome-
wide significance.
Conclusions—Atazanavir-associated hyperbilirubinemia is best predicted by considering
UGT1A1 genotype, baseline bilirubin, and baseline hemoglobin values in combination. Use of
ritonavir as a pharmacokinetic enhancer may have abrogated genetic associations with atazanavir
pharmacokinetics.
Keywords
HIV; atazanavir; pharmacogenomics; pharmacokinetics; UGT1A1
Introduction
The once-daily HIV-1 protease inhibitor atazanavir with low-dose ritonavir as a
pharmacokinetic enhancer (atazanavir/r) is generally safe, effective, and well tolerated [1-3]
in first-line regimen for HIV-1 infection [4]. Atazanavir increases plasma indirect bilirubin
concentrations by inhibiting uridine diphosphate glucuronosyltransferase (UGT) 1A1-
mediated bilirubin glucuronidation [5]. Approximately 40% of patients prescribed
atazanavir/r experience at least one indirect bilirubin elevation greater than 2.5 times the
upper limit of normal (i.e. grade 3) [1, 6-8], and approximately 5% at least 5 times the upper
limit of normal (i.e. grade 4) [1, 8]. While atazanavir-associated hyperbilirubinemia does not
indicate hepatic injury, some patients discontinue atazanavir due to icterus [3, 9, 10], or are
not prescribed atazanavir to avoid this possibility. Reliable baseline predictors of subsequent
hyperbilirubinemia could inform atazanavir/r prescribing.
Greater plasma atazanavir concentrations are associated with greater plasma bilirubin
elevations [7, 11]. Atazanavir undergoes phase I metabolism by hepatic cytochrome P450
(CYP) 3A isoforms [12] and is a substrate for membrane transporters including P-
glycoprotein (encoded by ABCB1), multidrug resistance-associated proteins (MRPs,
encoded by ABCC genes), and organic anion transporting polypeptides (OATPs, encoded by
SLCO genes) [13]. Candidate gene studies, most involving unboosted atazanavir, have
suggested associations between atazanavir pharmacokinetics and genetic polymorphisms in
ABCB1 [14-16], CYP3A5 [16-18], and NR1I2 (encoding pregnane X receptor) [16, 19].
Plasma atazanavir exposure is also influenced by non-genetic factors including concomitant
antiretrovirals [20-22], other medications such as rifampin {Acosta, 2007 #2192}, food [23],
and gastric acid blocking medications [12, 24].
Interindividual differences in plasma indirect bilirubin concentrations have been associated
with a UGT1A1 promoter tandem TA repeat. The UGT1A1*28 (TA) 7 allele is associated
with reduced UGT1A1 transcription as compared to UGT1A1*1 (TA)6 [25, 26]. Among
atazanavir recipients, UGT1A1*28 has been strongly associated with unconjugated
hyperbilirubinemia [27, 28], but inconsistently with atazanavir discontinuation[28, 29].
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The present study used a genome-wide approach to investigate genetic and non-genetic
associations with hyperbilirubinemia, and genetic predictors of plasma atazanavir
pharmacokinetics among subjects randomized to atazanavir/r-containing regimens in a
prospective clinical trial.
Methods
Study Participants
AIDS Clinical Trials Group (Protocol) A5202 (ClinTrials.gov NCT00118898) was a phase
IIIb equivalence study of four once-daily regimens for initial treatment of HIV-1 infection.
Primary results of A5202 have been previously reported [3, 30]. Briefly, A5202 subjects
enrolled from 2005 to 2007 were randomized to open-label atazanavir (300 mg) plus
ritonavir (100 mg), or efavirenz (600 mg), with either placebo-controlled abacavir/
lamivudine (600 mg/300 mg) or tenofovir DF/emtricitabine (300 mg/200 mg). Study
evaluations including indirect bilirubin and hemoglobin determinations were performed
before entry, at entry, at weeks 4, 8, 16 and 24, and every 12 weeks thereafter until the last
enrolled subject was followed 96 weeks. Bilirubin and hemoglobin were assayed at research
site clinical laboratories. Subjects in the present study were also the basis of a previous
analysis focused on UGT1A1*28 and premature discontinuation of atazanavir[28].
Atazanavir assays and plasma sampling
In A5202, plasma samples for atazanavir assays were obtained during any two scheduled
visits during the first 24 weeks of study. At one visit a sample was to be drawn immediately
before an observed dose and again 3-4 hours later. During the second visit a sample was
drawn between 5 and 12-15 hours post-dose (12 versus 15 hours depending on whether the
dose was in the morning or evening). Additional samples for atazanavir assay were collected
at week 48 and every 48 weeks thereafter, at final study visit, with first documented
virologic failure, and with medication change due to virologic failure.
Atazanavir was quantified using a previously reported reverse phase high performance
liquid chromatography (HPLC) method utilized at the University at Buffalo. Atazanavir was
separated on a Waters 5μm Symmetry™ shield RP C8, 3.0 × 150 mm column, with a
chromatographic system consisting of Waters 2695 Alliance Separations Module, and a 996
Photodiode Array Detector. The system was controlled by Waters Empower 2 software
Version 6.20.00.00 that collected all chromatographic data for analysis, generating a
calibration standard curve that was linear from 100-16,000 ng/mL.
Derivation of pharmacokinetic parameters
A model-based population pharmacokinetic analysis was performed using pharmacokinetic
samples collected at steady-state during the first 24 weeks of therapy. Concentration-time
data were analyzed using the first-order conditional estimation with interaction (FOCE-I)
method of the non-linear mixed effects modeling program NONMEM (version VII; ICON,
Ellicott City, MD). One- and two-compartment models were tested to identify an
appropriate structural model. A single compartment model with first-order absorption and
elimination was ultimately selected based on successful convergence (which two-
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compartment models did not) and goodness-of-fit plots (Supplementary Figure,
Supplemental Digital Content 1, http://links.lww.com/FPC/A688). Estimation of population
pharmacokinetic parameters included clearance, volume of distribution, and absorption rate
constant. Interindividual random effects were described on an exponential scale, while a
proportional error model was used to describe residual variability. Individual Bayesian
estimates of oral clearance values of atazanavir were estimated from the structural model.
Identifying genetic polymorphisms
Consent for genetic analyses was obtained under ACTG protocol A5128 [31]. The
Vanderbilt Institutional Review Boards and the ACTG approved this use of DNA. Genome-
wide data from the Illumina Human-1M-Duo platform were available from a separate
immunogenomics project [32]. Genetic data management and association analyses were
performed with PLINK version 1.07 [33]. Genetic ancestry was assigned using principal
components as described elsewhere [32]. Samples that did not group with African
American, European, or Hispanic populations were excluded. Analyses were performed
separately for African American, European, and Hispanic ancestry populations, and for all
three populations combined. Within each population, only polymorphisms with >98%
genotyping efficiency and >2% minor allele frequency were included in analyses. Samples
were censored for >2% missingness, excessive heterozygosity (|F| >0.1), or possible sex
misclassification. For sample pairs with high estimated relatedness as determined by identity
by descent (pi-hat > 0.125), only one sample was included in analyses. Final analyses
included as many as 925,738 assayed polymorphisms.
Targeted genotyping of UGT1A1 rs8175347 (i.e. (TA)5 *36, (TA)6 *1, (TA)7 *28, and
(TA)8 *37) was by fragment analysis as described elsewhere [34]. Laboratory personnel
with no knowledge of clinical data performed genotyping. Genotype assignment was
confirmed by visual inspection for electrophoresis peaks representing promoter TA tandem
repeats *36 (TA)5, *1 (TA)6, *28 (TA)7, and *37 (TA)8.
Association testing
Genetic associations were assessed using an uncorrected Wald test, as well as a linear
regression model that adjusted for covariates that by univariate analysis had P<0.05. For
atazanavir clearance, covariates included were body mass index, abacavir/lamivudine versus
tenofovir DF/emtricitabine assignment at randomization, sex, and occurrence of an
atazanavir concentration below limit of quantification. Peak bilirubin was defined as the
highest concentration during the first 24 weeks of atazanavir/r prescribing in A5202. For
peak bilirubin, univariate analyses showed associations with age, baseline bilirubin
concentration, baseline hemoglobin concentration, atazanavir clearance, and sex; after
correcting for hemoglobin, sex was no longer associated so was not included as a covariate.
To correct for population stratification, principal components were determined separately for
each population by EIGENSTRAT [35]. The first two principal components were included
as covariates for African American, European, and Hispanic groups. The first four principal
components generated with the combined population were included as covariates in the
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combined group analyses. P values were adjusted for genomic inflation factor based on
median chi-squared value.
From our genome-wide dataset, 13 functional polymorphisms in genes suggested to affect
atazanavir disposition were chosen a priori from PharmGKB[36] (CYP3A4 [12], CYP3A5
[12, 17, 18], ABCB1 [13], SLCO1B1[13], ABCC1 [13], ABCC2 [13], and NR1I2 [16, 37])
and previous atazanavir pharmacogenetic studies [14-19]. Similarly, a targeted set of 27
polymorphisms previously associated with bilirubin metabolism was assembled a priori.
Non-genetic statistical analyses were performed using R version 2.15.0 [38], using two-
sided tests for P values and confidence intervals, without adjusting for multiple
comparisons. Bonferroni-corrected genome-wide significance was defined as 5.0×10−8
giving a genome-wide family error rate of 0.05 for 925,738 comparisons. For the 13
polymorphisms in atazanavir disposition genes and 27 in bilirubin associated genes,
Bonferroni corrected P value thresholds for the single combined group were 0.0038 and
0.0019, respectively. For analyses of these a priori designated polymorphisms in all three
ethnic groups, Bonferroni corrected P values were 0.0013 and 0.00062 for pharmacokinetic
and bilirubin associated genes respectively.
Results
Study Participants
Among 928 subjects randomized to receive atazanavir/r-containing regimens in A5202,
atazanavir plasma concentration data were available from 815 subjects for population
pharmacokinetic modeling. Forty-eight out of 2195 atazanavir concentrations were below
the lower limit of quantitation (< 3%), and were substituted with concentration values of 50
ng/mL. Genome-wide assay data were available from 542 subjects [32], of who 475 (88%)
also had estimated atazanavir clearance and relevant covariate data available. Peak bilirubin
concentration and relevant covariates were available for 443 participants. Derivation of the
study population is shown in Figure 1. Baseline characteristics of study participants are
shown in Table 1.
Genetic associations with atazanavir pharmacokinetics
The parameter estimates (and relative standard error as percentage) for the one-compartment
pharmacokinetic model were 0.47 h−1 (11%) for the first-order absorption rate constant,
86.7 L (5%) for the volume of distribution, and 7.86 L/h (2%) for apparent oral clearance
with an interindividual variability of 36% (8%). The median estimated atazanavir clearance
for subjects with genome-wide assay data was 7.75 L/hr (95% C.I. 7.54 to 7.96 L/hr). No
polymorphism was associated with clearance at genome-wide significance, whether
considering each population separately, or in a combined analysis including all three
populations. Of the 10 polymorphisms with the lowest P values in the combined population,
none were in genes with apparent relevance to drug disposition (Table 2, top). Data for all
polymorphisms associated with estimated atazanavir clearance at P <5.0×10–5 are listed in
Supplemental Table 1, Supplemental Digital Content 2, http://links.lww.com/FPC/A689. Of
the 13 polymorphisms designated a priori for possible associations with atazanavir
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clearance, none were significant after correcting for multiple comparisons in the combined
population. There were trends toward nominal associations with rs4149056 in SLCO1B1 (β=
−0.089, P=0.049) and rs776746 in CYP3A5 (β= 0.076, P=0.097), as shown in Table 3.
When each population was analyzed separately, of the 13 targeted polymorphisms,
rs2235015 in ABCB1 was nominally associated with clearance among Hispanics
(PClearance=0.013). Additionally, clearance was nominally associated in African Americans
with rs1722273 in ABCC2 (P=0.033) and in Hispanics with rs776746 in CYP3A5 (P=0.046).
None were significant after Bonferroni correction.
Associations with indirect bilirubin concentrations
Among the 443 participants included in analyses for genomic associations with peak
bilirubin concentrations, median baseline indirect bilirubin was 0.5 mg/dL (IQR 0.3 - 0.8
mg/dL), and median peak indirect bilirubin during the first 24 weeks of therapy was 2.2
mg/dL (IQR 1.6 - 3.4 mg/dL). By univariate analysis, greater baseline (i.e. pre-atazanavir)
bilirubin concentrations were significantly associated with male sex (P=1.4×10−5) and
greater baseline hemoglobin concentration (P=7.1×10−6, β=0.094 bilirubin mg/dL per
hemoglobin g/dL). In genome-wide analysis of baseline indirect bilirubin in the combined
population, 10 polymorphisms were genome-wide significant, each in or near UGT1A1. The
smallest P value was for rs6742078 (P=1.8×10−9, β=0.30 mg/dL per T allele).
Clinical variables associated with greater on-treatment peak indirect bilirubin concentration
by univariate analysis included greater baseline indirect bilirubin concentration
(P=2.61×10−25, β=0.36), greater baseline hemoglobin concentration (P=1.37x10−13, β=0.12
(mg/dL)/(g/dL)), slower estimated atazanavir clearance (P=8.98x10−9, β= −0.55 (mg/dL) per
(L/h)), and younger age (P=4.93x10−4, β= −0.0097 mg/dL per year). There was no
association between on-treatment peak indirect bilirubin concentration and either baseline
alanine aminotransferase (ALT, P=0.72) or baseline hepatitis C seropositivity (P= 0.16). In
multivariate genome-wide analysis of peak on-treatment indirect bilirubin concentration in
the combined population (adjusting for baseline bilirubin concentration, baseline
hemoglobin concentration, age, atazanavir clearance, and the top 4 principal components),
10 polymorphisms in or near UGT1A1 were genome-wide significant, the smallest P value
being for rs887829. In this analysis, greater peak bilirubin was associated with rs887829 T
allele (P=6.4×10−12, β=0.30 mg/dL per T allele), greater baseline bilirubin concentration
(P=6.7×10−12, β=0.22), slower estimated atazanavir clearance (P=8.6×10−11, β= −0.51
(mg/dL)/(L/hr)), and greater baseline hemoglobin concentration (P=4.9×10−13, β=0.098
(mg/dL)/(g/dL)). After controlling for rs887829, no additional polymorphisms were
genome-wide significant. Of 27 targeted polymorphisms selected a priori for possible
association with bilirubin, only those in or near UGT1A1 were significant after Bonferroni
correction (Supplemental Table 2, Supplemental Digital Content 3, http://
links.lww.com/FPC/A690).
In addition to genome-wide assay data, the UGT1A1 tandem TA repeat (rs8175347 which
defines UGT1A1 *28, *36 and *37 alleles) was directly assayed. Among A5202 subjects,
rs8175347 was in almost complete linkage disequilibrium with rs887829 (R2=0.99), so was
not informative beyond rs887829.
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Prediction of peak on-treatment bilirubin
Associations between peak plasma bilirubin >3.0 mg/dL (an approximate concentration
above which jaundice icterus tends to be noticeable) and rs887829 genotype were
considered in relation to a baseline bilirubin threshold of 0.5 mg/dL and a baseline
hemoglobin threshold of 14 g/dL. These baseline thresholds approximate median values. As
shown in Figure 2, the positive predictive value of baseline bilirubin ≥0.5 mg/dL and
baseline hemoglobin ≥14 g/dL for peak bilirubin >3.0 mg/dL was 0.51 (95% C.I 0.40 to
0.57). This increased to 0.85 (95% C.I., 0.65 to 0.96) by also including rs887829 TT
homozygosity. Conversely, the positive predictive value of baseline bilirubin <0.5 mg/dL
and baseline hemoglobin <14 g/dL for peak bilirubin ≤3.0 mg/dL was 0.91 (95% C.I., 0.85
to 0.95). This increased to 0.96 (95% C.I., 0.88 to 0.99) by also including rs887829 CC
homozygosity. Among individual with rs887829 CT heterozygosity and/or representing
discordant baseline bilirubin and hemoglobin strata, the likelihood of peak bilirubin greater
or less than 3.0 mg/dL reflected ordinal effects of each of the three variables (Figure 2).
Additional analyses that considered several alternative peak plasma bilirubin thresholds
greater than 3.0 mg/dL did not substantially improve prediction (data not shown).
Multivariable models assessed the extent to which interindividual variability in peak on-
treatment bilirubin concentrations could be explained by genetic and non-genetic factors,
based on adjusted-R2 values (Table 4). A model that included all four variables (baseline
bilirubin concentration, baseline hemoglobin concentration, estimated plasma atazanavir
clearance, and rs887829 genotype) explained 41.3% of variability in peak on-treatment
bilirubin concentrations (Model 6). In models that included baseline hemoglobin
concentration and estimated plasma atazanavir clearance, adding either baseline bilirubin
concentration or rs887829 genotype contributed comparably to peak on-treatment bilirubin
concentrations (33.4% in Model 1 vs. 33.6% in Model 2). In models that included baseline
hemoglobin concentration, adding either baseline bilirubin concentration or rs887829
genotype contributed comparably to peak on-treatment bilirubin concentrations (30.3% in
Model 3 vs. 26.4% in Model 4).
Discussion
We used a genome-wide approach to investigate associations between human genetic
variants, pharmacokinetics, and indirect bilirubin concentrations among subjects randomized
to receive atazanavir/r in ACTG protocol A5202. In a multivariate model, variables
independently associated with peak on-treatment indirect bilirubin concentrations were
UGT1A1 rs887829 genotype, baseline bilirubin concentration, baseline hemoglobin
concentration, and atazanavir clearance, which together explained 41.3% of interindividual
variability. The best pre-treatment predictor of peak on-treatment indirect bilirubin ≤3.0
mg/dL (i.e. excluding atazanavir pharmacokinetic data) was the combination of rs887829
CC homozygosity, lower bilirubin concentration, and lower hemoglobin concentration.
Conversely, the best pre-treatment predictor of peak on-treatment indirect bilirubin >3.0
mg/dL was the combination of rs887829 TT homozygosity, greater bilirubin concentration,
and greater hemoglobin concentration.
Johnson et al. Page 7
Pharmacogenet Genomics. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Previous candidate gene studies have suggested associations between atazanavir
pharmacokinetics and polymorphisms in drug metabolism and/or transporter genes. The
present study did not replicate such associations, nor did we identify new genetic
associations with atazanavir pharmacokinetics among targeted polymorphisms in genes
relevant to atazanavir disposition or in genome-wide analyses. We hypothesize that
ritonavir, by inhibiting the activity of CYP isoforms including CYP3A5, may have masked
potential genetic associations with atazanavir pharmacokinetics. Drug metabolism and
transporter gene polymorphisms were therefore not included in multivariate models for on-
treatment bilirubin concentrations.
In the combined population analysis of atazanavir clearance there were trends toward
nominally significant associations with SLCO1B1 521T→C (rs4149056) and the CYP3A5*3
loss-of-function polymorphism (rs776746). Among Hispanics, rs776746 was also nominally
associated with clearance. However, neither polymorphism was significant after Bonferroni
correction among Blacks, Whites, or Hispanics analyzed separately. Multiple prior studies
have associated SLCO1B1 rs4149056 with increased plasma lopinavir concentrations among
patients prescribed lopinavir/ritonavir[39-42][43] and one study associated this
polymorphisms with decreased plasma amprenavir concentrations among patients prescribed
fos-amprenavir/ritonavir [41]. A prior study of 31 HIV-negative individuals suggested an
association between CYP3A5 genotype and plasma clearance of atazanavir (without
ritonavir), which lessened when combined with ritonavir [17]. The present study did not
replicate ABCB1 3435C→T (rs1045642), which has been reported to be associated with
pharmacokinetics for atazanavir without ritonavir [14] and with ritonavir [15]. While we
cannot explain the failure of ABCB1 3435C→T to replicate in our study, reported
associations of this polymorphism with pharmacokinetics and other phenotypes for many
drugs have failed to replicate. The NR1I2 polymorphism 63396C→T (rs2472677) reported
to be associated with atazanavir pharmacokinetics [19, 37] was not assayed in the present
study.
The UGT1A1 rs887829 polymorphism is a well-established predictor of increased plasma
indirect bilirubin concentrations in the general population (i.e. Gilbert trait) [44-46], and
accounts for approximately 15% of variation in African Americans [44] and Europeans [46].
In the present study rs887829 was in almost complete linkage disequilibrium with
UGT1A1*28 (rs8175347) genotype. Previous studies have associated UGT1A1*28 with
greater indirect bilirubin elevations among HIV-infected individuals prescribed indinavir
[27] or atazanavir [27, 28]. In a study of patients HIV-infected patients prescribed indinavir
and HIV-negative individuals, increased likelihood of hyperbilirubinemia was associated
with multiple polymorphisms in UGT1A genes including UGT1A1*28, UGT1A7
(rs7586110), UGT1A7 (rs17868323), and UGT1A3 (rs3806596). These associations were
also seen in the present study, but disappeared after correcting for rs887829.
Polymorphisms in genes beyond UGT1A1 have been reported to be associated with serum
bilirubin concentrations in the general population, including ABCC2, ABCB4, ABCB11,
ATP8B1, SLCO1B1 [46], SLCO1B3 and G6PD [45]. In addition, bilirubin concentrations
have been associated with ABCB1 3435C→T among patients prescribed atazanavir without
ritonavir but not with ritonavir [17], although results have been inconsistent [14]. The
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present study did not replicate genetic predictors of hyperbilirubinemia beyond rs887829
(Supplemental Table 2, Supplemental Digital Content 3, http://links.lww.com/FPC/A690).
It is not unexpected that baseline bilirubin is associated was peak on-treatment indirect
bilirubin concentrations, independent of UGT1A1 rs887829 genotype. In population-based
studies, genetic polymorphisms have explained less than 50% of interindividual variability
in bilirubin concentrations. Non-genetic factors such as increased rates of red blood cell
turnover (i.e. increased bilirubin production) are certain to affect baseline bilirubin
concentrations. The association between peak on-treatment indirect bilirubin concentrations
and higher hemoglobin concentrations may be the consequence of a greater mass of red
blood cells from which to produce bilirubin.
In genetic association studies, unrecognized population stratification can lead to false
discovery. This was addressed in the present study by correcting for genetic ancestry using
principal components in the total population analysis as well as in each race/ethnicity group
analyzed separately.
There were limitations to the present study. Some previously reported pharmacogenetic
associations have involved atazanavir without ritonavir [14, 16, 19, 47], and a decreased
effect of genetic variants has been suggested for atazanavir with ritonavir [15, 17]. In the
present study, genetic associations with atazanavir pharmacokinetics may have been
abrogated by the use of atazanavir with ritonavir. Clearance was estimated from sparse
pharmacokinetic data applied to a population pharmacokinetic model, and errors in the
model would have misestimated pharmacokinetic parameters. However, Colombo et al
compared population pharmacokinetic modeling for a rich versus a sparse data set and found
similar individual variances between the two groups [24]. Although we used a genome-wide
approach, it is possible that polymorphisms not assayed herein, such as rare variants and
copy number polymorphisms, or with weaker effect sizes than can be detected with this
sample size. Our sample size of 443 participants for bilirubin analyses and 475 participants
for pharmacokinetic analyses may have limited our ability to identify polymorphisms with
small effects. However, unlike GWAS of complex traits such as diabetes, large effect sizes
with drug metabolism/transport genes and off-target genes often reveal genome-wide
significant associations with modest sample sizes. For example, genetic prediction of
abacavir hypersensitivity is genome-wide significant (P<5.0×10−8) with only 15 cases and
200 controls [48], statin response with only 85 cases and 90 controls [49], and nevirapine
rash with only 71 cases and 77 controls [50].
In summary, peak plasma indirect bilirubin concentrations during the first 24 weeks of
therapy are associated with UTG1A1 rs887829, baseline bilirubin concentrations, baseline
hemoglobin concentrations, and atazanavir clearance. It is possible that therapeutic drug
monitoring with atazanavir dose reduction in selected individuals could reduce
hyperbilirubinemia, but this question was not addressed by the present study. Consideration
of genetic and clinical laboratory data at baseline best stratifies risk for subsequent
development of on-treatment hyperbilirubinemia.
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Figure 1. Derivation of the study population
Of 928 individuals randomized to atazanavir-containing regimens in A5202, a total of 464
were ultimately included in analyses for genetic associations with baseline indirect bilirubin,
444 in analyses for genetic associations with peak indirect bilirubin, and 474 in analyses for
genetic associations with atazanavir clearance.
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Figure 2. Predictive values of baseline bilirubin, baseline hemoglobin, and rs887829 genotype for
peak on-treatment bilirubin
For these analyses a cut-off of 3.0 mg/dL was used. Each dot represents a different
individual. Positive predictive values and 95% confidence intervals are provided. Positive
predictive value = (number of participants with peak bilirubin >3.0 mg/dL) / (all individuals
with the predictor variables indicated). BBR, baseline bilirubin; HGB, baseline hemoglobin.
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Table 1
Baseline characteristics of study subjects
Pharmacokinetic association analyses (N = 475) Bilirubin association analyses (N = 443)
Race/ethnicity
    Black, n (%) 145 (31%) 135 (30%)
    White, n (%) 212 (45%) 204 (46%)
    Hispanic, n (%) 118 (25%) 104 (23%)
Female 13.5% 14.2%
Randomized to TDF/FTCa 51% 51%
Median BMIb in kg/m2 (SDc) 25.7 (5.15) 25.8 (5.19)
Median age in years (SD) 38.5 (10.3) 38.8 (10.3)
Median baseline bilirubin in mg/dL (IQRd) - 0.5 (0.3 - 0.8)
Median baseline hemoglobin in g/dL (IQR) - 13.8 (12.4 - 14.9)
a
TDF/FTC, tenofovir DF/emtricitabine;
b
BMI, body mass index
cSD, standard deviation
d
IQR, interquartile range
Pharmacogenet Genomics. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Johnson et al. Page 17
Ta
bl
e 
2
Po
ly
m
or
ph
ism
s w
ith
 th
e 
lo
w
es
t P
-v
al
ue
s f
or
 a
ss
oc
ia
tio
n 
w
ith
 e
sti
m
at
ed
 p
la
sm
a 
at
az
an
av
ir 
cl
ea
ra
nc
e 
in
 th
e 
co
m
bi
ne
d 
po
pu
la
tio
n 
an
al
ys
is.
SN
P
O
ve
ra
ll
O
ve
ra
ll 
β
G
en
e
D
ist
an
ce
A
fA
m
 M
A
F
A
fA
m
 β
H
isp
 M
A
F
H
isp
 β
Eu
ro
 M
A
F
Eu
ro
 β
As
so
ci
at
io
ns
 w
ith
 cl
ea
ra
nc
e
rs
18
99
97
9
2.
38
×1
0−
6
0.
21
BI
CC
1
0
0.
34
0.
18
0.
26
0.
23
0.
24
0.
22
rs
23
35
46
2
3.
81
×1
0−
6
0.
21
FL
YW
CH
2
0
0.
25
0.
2
0.
3
0.
16
0.
27
0.
2
rs
17
15
69
16
5.
05
×1
0−
6
−
0.
2
NU
D
T1
2
11
58
30
5
0.
1
−
0.
25
N
A
N
A
0.
15
−
0.
26
rs
47
19
77
2
6.
07
×1
0−
6
0.
2
M
PP
6
−
18
49
33
0.
44
0.
11
0.
48
0.
3
0.
41
0.
19
rs
80
41
91
1
1.
26
×1
0−
5
0.
19
D
U
O
X1
0
0.
17
0.
26
0.
22
0.
3
0.
22
0.
1
rs
54
01
71
1.
28
×1
0−
5
0.
19
LP
AR
1
−
53
66
2
0.
2
0.
3
0.
1
0.
25
0.
1
0.
1
rs
57
51
07
1.
28
×1
0−
5
0.
19
LP
AR
1
−
52
14
5
0.
2
0.
3
0.
1
0.
25
0.
1
0.
1
rs
21
10
69
1.
33
×1
0−
5
0.
19
PR
K
G
1
0
0.
46
0.
14
0.
5
0.
21
0.
44
0.
2
rs
69
29
40
0
1.
37
×1
0−
5
−
0.
19
C6
or
f10
5
0
0.
18
−
0.
17
0.
28
−
0.
15
0.
42
−
0.
22
rs
10
90
26
46
1.
42
×1
0−
5
−
0.
19
SF
N
−
66
48
0.
19
−
0.
25
0.
24
−
0.
1
0.
42
−
0.
21
Fo
ot
no
te
: O
ve
ra
ll 
P 
an
d 
β v
al
ue
s a
re
 b
as
ed
 o
n 
co
m
bi
ne
d 
po
pu
la
tio
n 
an
al
ys
es
 w
ith
 A
fri
ca
n 
A
m
er
ic
an
s, 
Eu
ro
pe
an
s a
nd
 H
isp
an
ic
s. 
D
ist
an
ce
 re
fle
ct
s b
as
e 
pa
irs
 fr
om
 th
e 
ne
ar
es
t g
en
e,
 w
ith
 z
er
o 
in
di
ca
tin
g
lo
ca
tio
n 
w
ith
in
 th
e 
ge
ne
. A
fA
m
, H
isp
 a
nd
 E
ur
o 
M
A
F 
in
di
ca
te
 m
in
or
 a
lle
le
 fr
eq
ue
nc
ie
s i
n 
th
e 
A
fri
ca
n-
A
m
er
ic
an
, H
isp
an
ic
 a
nd
 E
ur
op
ea
n 
po
pu
la
tio
ns
. A
fA
m
, H
isp
 a
nd
 E
ur
o 
β a
re
 c
al
cu
la
te
d 
β f
or
 e
ac
h 
ra
ce
/
et
hn
ic
ity
 g
ro
up
 a
na
ly
ze
d 
se
pa
ra
te
ly
.
Pharmacogenet Genomics. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Johnson et al. Page 18
Ta
bl
e 
3
A
ss
oc
ia
tio
ns
 b
et
w
ee
n 
ta
rg
et
ed
 d
ru
g 
m
et
ab
ol
ism
 a
nd
 tr
an
sp
or
te
r g
en
e 
po
ly
m
or
ph
ism
s a
nd
 p
la
sm
a 
at
az
an
av
ir 
cl
ea
ra
nc
e.
SN
P
P c
le
ar
an
ce
β c
le
ar
an
ce
C
H
R
Po
sit
io
n 
(b
p)
G
en
e
A
fA
m
 M
A
F
H
isp
 M
A
F
Eu
ro
 M
A
F
A
fA
m
 β C
le
ar
an
ce
H
isp
 β C
le
ar
an
ce
Eu
ro
 β C
le
ar
an
ce
rs
10
26
42
72
0.
73
−
0.
01
6
7
99
10
07
71
CY
P3
A5
0.
13
-
-
−
0.
02
6
-
-
rs
10
45
64
2
0.
23
−
0.
05
4
7
86
97
65
81
AB
CB
1
0.
23
0.
41
0.
43
−
0.
01
5
−
0.
08
2
0.
03
8
rs
11
28
50
3
1
−
0.
00
01
8
7
87
01
75
37
AB
CB
1
0.
23
0.
41
0.
45
−
0.
03
7
−
0.
04
6
0.
04
7
rs
17
22
27
23
0.
36
−
0.
04
1
10
10
15
85
98
6
AB
CC
2
0.
06
1
0.
04
4
0.
05
−
0.
18
0.
07
8
0.
00
23
rs
22
29
10
9
0.
76
−
0.
01
3
7
87
01
77
45
AB
CB
1
-
0.
04
2
0.
03
9
-
−
0.
13
0.
11
rs
22
35
01
5
0.
49
0.
03
1
7
87
03
75
00
AB
CB
1
0.
33
0.
19
0.
18
−
0.
08
3
0.
22
0.
03
rs
22
38
47
6
0.
39
−
0.
03
8
16
16
12
13
73
AB
CC
1
0.
04
5
0.
11
0.
04
8
−
0.
05
9
−
0.
11
−
0.
00
07
8
rs
22
73
69
7
0.
61
0.
02
3
10
10
15
53
80
5
AB
CC
2
0.
15
0.
16
0.
2
0.
04
4
0.
05
6
0.
00
24
rs
24
62
40
0.
48
0.
03
2
16
16
02
65
25
AB
CC
1
0.
1
0.
2
0.
17
0.
01
3
0.
04
0.
05
rs
35
59
2
0.
62
−
0.
02
2
16
16
04
93
24
AB
CC
1
0.
5
0.
3
0.
25
−
0.
05
9
0.
00
68
−
0.
04
5
rs
41
49
05
6
0.
04
9
−
0.
08
9
12
21
22
28
16
SL
CO
1B
1
0.
03
1
0.
15
0.
17
−
0.
09
3
−
0.
08
2
−
0.
11
rs
77
67
46
0.
09
7
0.
07
6
7
99
10
84
75
CY
P3
A5
0.
31
0.
23
0.
07
1
−
0.
11
0.
18
−
0.
01
4
rs
81
87
71
0
0.
98
0.
00
08
5
10
10
16
01
28
4
AB
CC
2
0.
16
0.
05
4
0.
05
1
−
0.
07
7
0.
07
0.
02
8
Fo
ot
no
te
: T
he
 P
 a
nd
 β 
v
al
ue
s a
t t
he
 le
ft 
ar
e 
ba
se
d 
on
 c
om
bi
ne
d 
po
pu
la
tio
n 
an
al
ys
es
 w
ith
 A
fri
ca
n 
A
m
er
ic
an
s, 
Eu
ro
pe
an
s A
m
er
ic
an
s, 
an
d 
H
isp
an
ic
s. 
D
ist
an
ce
 re
fle
ct
s b
as
e 
pa
irs
 fr
om
 th
e 
ne
ar
es
t g
en
e,
 w
ith
ze
ro
 in
di
ca
tin
g 
lo
ca
tio
n 
w
ith
in
 th
e 
ge
ne
. A
fA
m
, H
isp
 a
nd
 E
ur
o 
M
A
F 
in
di
ca
te
 m
in
or
 a
lle
le
 fr
eq
ue
nc
ie
s i
n 
th
e 
A
fri
ca
n-
A
m
er
ic
an
, H
isp
an
ic
 a
nd
 E
ur
op
ea
n 
po
pu
la
tio
ns
. A
fA
m
, H
isp
 a
nd
 E
ur
o 
β a
re
 c
al
cu
la
te
d 
β
fo
r e
ac
h 
ra
ce
/e
th
ni
ci
ty
 g
ro
up
 a
na
ly
ze
d 
se
pa
ra
te
ly
.
Pharmacogenet Genomics. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Johnson et al. Page 19
Ta
bl
e 
4
A
dju
ste
d R
2  
fo
r p
re
di
ct
io
n 
of
 p
ea
k 
bi
lir
ub
in
 o
f v
ar
io
us
 m
od
el
s
M
od
el
 #
1
2
3
4
5
6
7
8
H
G
B
+
+
+
+
+
+
+
+
A
TV
 c
le
ar
an
ce
+
+
0
0
0
+
+
0
B
as
el
in
e 
Bi
lir
ub
in
+
0
+
0
+
+
0
0
rs
88
78
29
0
+
0
+
+
+
0
0
R
2  
A
dju
ste
d*
0.
33
4
0.
33
6
0.
30
3
0.
26
4
0.
36
8
0.
41
3
0.
18
1
0.
12
5
*
A
dju
ste
d t
o c
om
pe
nsa
te 
for
 th
e n
um
be
r o
f v
ari
ab
les
 in
clu
de
d i
n t
he
 m
od
el.
Pharmacogenet Genomics. Author manuscript; available in PMC 2015 April 01.
